Squarepoint Ops LLC Purchases Shares of 21,362 Artivion, Inc. $AORT

Squarepoint Ops LLC purchased a new position in shares of Artivion, Inc. (NYSE:AORT) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 21,362 shares of the company’s stock, valued at approximately $664,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Next Century Growth Investors LLC boosted its holdings in shares of Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock valued at $25,140,000 after acquiring an additional 530,122 shares during the last quarter. Bank of America Corp DE raised its holdings in Artivion by 22.8% in the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock valued at $20,062,000 after acquiring an additional 119,634 shares during the last quarter. Invesco Ltd. boosted its stake in Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after buying an additional 139,370 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Artivion by 5.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 376,052 shares of the company’s stock worth $9,243,000 after purchasing an additional 17,860 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its stake in Artivion by 20.8% during the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after purchasing an additional 63,205 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Price Performance

AORT stock opened at $47.20 on Wednesday. The business’s fifty day moving average price is $45.18 and its 200 day moving average price is $39.65. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $2.24 billion, a PE ratio of -196.67 and a beta of 1.60.

Artivion (NYSE:AORT) last released its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.Artivion’s quarterly revenue was up 18.9% on a year-over-year basis. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Oppenheimer reissued an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Wall Street Zen raised Artivion from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. JMP Securities raised their price objective on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Finally, Citizens Jmp upped their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

Insider Activity

In other Artivion news, CAO Amy Horton sold 4,572 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $44.42, for a total transaction of $203,088.24. Following the sale, the chief accounting officer directly owned 130,058 shares in the company, valued at $5,777,176.36. This represents a 3.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elizabeth A. Hoff sold 4,200 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $45.10, for a total transaction of $189,420.00. Following the completion of the transaction, the director directly owned 27,189 shares of the company’s stock, valued at $1,226,223.90. This represents a 13.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 234,511 shares of company stock worth $10,612,452 over the last 90 days. Company insiders own 8.10% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.